Specificity of the Ester Bond Forming Condensation Enzyme SgcC5 in C-1027 Biosynthesis

被引:15
作者
Lin, Shuangjun [1 ]
Huang, Tingting [3 ]
Horsman, Geoff P. [1 ]
Huang, Sheng-Xiong [3 ]
Guo, Xun [3 ]
Shen, Ben [1 ,2 ,3 ,4 ]
机构
[1] Univ Wisconsin, Div Pharmaceut Sci, Madison, WI 53705 USA
[2] Scripps Res Inst, TSRI, Nat Prod Lib Initiat, Jupiter, FL 33458 USA
[3] Scripps Res Inst, Dept Chem, Jupiter, FL 33458 USA
[4] Scripps Res Inst, Dept & Mol Therapeut, Jupiter, FL 33458 USA
基金
加拿大自然科学与工程研究理事会;
关键词
ANTITUMOR ANTIBIOTIC C-1027; 4-METHYLIDENEIMIDAZOLE-5-ONE-CONTAINING TYROSINE AMINOMUTASE; RESPONSES; DOMAIN; BREAKS; DRUG;
D O I
10.1021/ol300720s
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The SgcC5 condensation enzyme catalyzes the attachment of SgcC2-tethered (S)-3-chloro-5-hydroxy-beta-tyrosine (2) to the enediyne core in C-1027 (1) biosynthesis. It is reported that SgcC5 (i) exhibits high stereospecificity toward the (S)-enantiomers of SgcC2-tethered beta-tyrosine and analogues as donors, (ii) prefers the (R)-enantiomers of 1-phenyl-1,2-ethanediol (3) and analogues, mimicking the enediyne core, as acceptors, and (iii) can recognize a variety of donor and acceptor substrates to catalyze their regio- and stereospecific ester bond formations.
引用
收藏
页码:2300 / 2303
页数:4
相关论文
共 17 条
[1]   C-1027, A Radiomimetic Enediyne Anticancer Drug, Preferentially Targets Hypoxic Cells [J].
Beerman, Terry A. ;
Gawron, Loretta S. ;
Shin, Seulkih ;
Shen, Ben ;
McHught, Mary M. .
CANCER RESEARCH, 2009, 69 (02) :593-598
[2]   Kinetic analysis of the 4-methylideneimidazole-5-one-containing tyrosine aminomutase in enediyne antitumor antibiotic C-1027 biosynthesis [J].
Christenson, SD ;
Wu, WM ;
Spies, MA ;
Shen, B ;
Toney, MD .
BIOCHEMISTRY, 2003, 42 (43) :12708-12718
[3]   A novel 4-methylideneimidazole-5-one-containing tyrosine aminomutase in enediyne antitumor antibiotic C-1027 biosynthesis [J].
Christenson, SD ;
Liu, W ;
Toney, MD ;
Shen, B .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (20) :6062-6063
[4]   The structure of L-tyrosine 2,3-aminomutase from the C-1027 enediyne antitumor antibiotic biosynthetic pathway [J].
Christianson, Carl V. ;
Montavon, Timothy J. ;
Van Lanen, Steven G. ;
Shen, Ben ;
Bruner, Steven D. .
BIOCHEMISTRY, 2007, 46 (24) :7205-7214
[5]   Chirality of peptide bond-forming condensation domains in nonribosomal peptide synthetases:: The C5 domain of tyrocidine synthetase is a DCL catalyst [J].
Clugston, SL ;
Sieber, SA ;
Marahiel, MA ;
Walsh, CT .
BIOCHEMISTRY, 2003, 42 (41) :12095-12104
[6]   A NEW MACROMOLECULAR ANTITUMOR ANTIBIOTIC, C-1027 .1. DISCOVERY, TAXONOMY OF PRODUCING ORGANISM, FERMENTATION AND BIOLOGICAL-ACTIVITY [J].
HU, J ;
XUE, YC ;
XIE, MY ;
ZHANG, R ;
OTANI, T ;
MINAMI, Y ;
YAMADA, Y ;
MARUNAKA, T .
JOURNAL OF ANTIBIOTICS, 1988, 41 (11) :1575-1579
[7]   Designer enediynes generate DNA breaks, interstrand cross-links, or both, with concomitant changes in the regulation of DNA damage responses [J].
Kennedy, Daniel R. ;
Ju, Jianhua ;
Shen, Ben ;
Beerman, Terry A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (45) :17632-17637
[8]   Single chemical modifications of the C-1027 enediyne core, a radiomimetic antitumor drug, affect both drug potency and the role of ataxia-telangiectasia mutated in cellular responses to DNA double-strand breaks [J].
Kennedy, Daniel R. ;
Gawron, Loretta S. ;
Ju, Jianhua ;
Liu, Wen ;
Shen, Ben ;
Beerman, Terry A. .
CANCER RESEARCH, 2007, 67 (02) :773-781
[9]   Characterization of the two-component, FAD-dependent monooxygenase SgcC that requires carrier protein-tethered substrates for the biosynthesis of the enediyne antitumor antibiotic C-1027 [J].
Lin, Shuangjun ;
Van Lanen, Steven G. ;
Shen, Ben .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (20) :6616-6623
[10]   Regiospecific chlorination of (S)-ß-Tyrosyl-S-Carrier protein catalyzed by SgcC3 in the biosynthesis of the enediyne antitumor antibiotic C-1027 [J].
Lin, Shuangjun ;
Van Lanen, Steven G. ;
Shen, Ben .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (41) :12432-12438